AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
cimetidine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| histamine-H2-receptor antagonists, cimetidine derivatives | 645 | 51481-61-9 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.80 | g | O |
| 0.80 | g | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
| S (Water solubility) | 6.20 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 62 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 158.51 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 60 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 1.20 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 8.10 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.78 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 2.20 hours | Lombardo F, Berellini G, Obach RS |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,JAK2,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPK9,MARK4,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PIK3CD,PIM2,PRKDC,SIK2,STK33,SYK,TEK,TTK | 36 | |||
| kinase-selectivity-class | GRK2 | 1 | |||
| mdck-mdr1-bcrp-efflux | MDCK-MDR1-BCRP efflux ratio | 1.026 | Moderate | 0.67 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pld-class | Phospholipidosis risk class (1 = positive, 0 = negative) | 0 | Moderate | 0.67 | |
| rat-kpuu-brain | Rat brain Kpuu | 0.019 | % | Moderate | 0.67 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Aug. 16, 1977 | FDA |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Body tinea | 169.12 | 13.56 | 45 | 16412 | 2103 | 90609887 |
| Urine abnormality | 166.77 | 13.56 | 60 | 16397 | 7677 | 90604313 |
| Inhibitory drug interaction | 151.89 | 13.56 | 45 | 16412 | 3118 | 90608872 |
| Infection susceptibility increased | 142.30 | 13.56 | 45 | 16412 | 3881 | 90608109 |
| Urine leukocyte esterase positive | 133.12 | 13.56 | 41 | 16416 | 3241 | 90608749 |
| Poor quality sleep | 121.50 | 13.56 | 68 | 16389 | 24625 | 90587365 |
| Lymphocyte count decreased | 116.51 | 13.56 | 75 | 16382 | 34975 | 90577015 |
| Glucose tolerance impaired | 114.54 | 13.56 | 46 | 16411 | 7939 | 90604051 |
| Hyperlipidaemia | 93.82 | 13.56 | 56 | 16401 | 22860 | 90589130 |
| Purpura | 93.18 | 13.56 | 48 | 16409 | 14730 | 90597260 |
| Impaired work ability | 89.07 | 13.56 | 51 | 16406 | 19275 | 90592715 |
| Culture urine positive | 87.47 | 13.56 | 31 | 16426 | 3794 | 90608196 |
| Bone density decreased | 85.96 | 13.56 | 48 | 16409 | 17297 | 90594693 |
| Impaired quality of life | 83.08 | 13.56 | 52 | 16405 | 23092 | 90588898 |
| Urine ketone body present | 75.18 | 13.56 | 25 | 16432 | 2527 | 90609463 |
| Blood urine present | 65.00 | 13.56 | 40 | 16417 | 17238 | 90594752 |
| Drug intolerance | 62.51 | 13.56 | 5 | 16452 | 447586 | 90164404 |
| Chronic kidney disease | 62.26 | 13.56 | 60 | 16397 | 50131 | 90561859 |
| Torsade de pointes | 61.88 | 13.56 | 37 | 16420 | 15145 | 90596845 |
| Erythema | 61.05 | 13.56 | 131 | 16326 | 229115 | 90382875 |
| Oral herpes | 59.34 | 13.56 | 49 | 16408 | 33475 | 90578515 |
| Skin disorder | 55.47 | 13.56 | 49 | 16408 | 36657 | 90575333 |
| Joint swelling | 55.22 | 13.56 | 12 | 16445 | 503288 | 90108702 |
| Anaphylactoid reaction | 51.43 | 13.56 | 22 | 16435 | 4446 | 90607544 |
| Neutrophil count increased | 51.25 | 13.56 | 36 | 16421 | 19354 | 90592636 |
| Cellulitis | 47.47 | 13.56 | 70 | 16387 | 91267 | 90520723 |
| White blood cell count decreased | 42.75 | 13.56 | 94 | 16363 | 167015 | 90444975 |
| Cataract | 41.49 | 13.56 | 58 | 16399 | 72034 | 90539956 |
| Rheumatoid arthritis | 41.09 | 13.56 | 8 | 16449 | 362606 | 90249384 |
| Wound | 40.61 | 13.56 | 4 | 16453 | 302976 | 90309014 |
| Keratitis | 40.49 | 13.56 | 18 | 16439 | 3988 | 90608002 |
| Treatment failure | 38.26 | 13.56 | 5 | 16452 | 303923 | 90308067 |
| Systemic lupus erythematosus | 36.98 | 13.56 | 10 | 16447 | 361886 | 90250104 |
| Drug interaction | 36.69 | 13.56 | 122 | 16335 | 276331 | 90335659 |
| Specific gravity urine decreased | 36.68 | 13.56 | 11 | 16446 | 794 | 90611196 |
| Band sensation | 36.59 | 13.56 | 12 | 16445 | 1161 | 90610829 |
| Arthropathy | 35.81 | 13.56 | 11 | 16446 | 366231 | 90245759 |
| Alanine aminotransferase increased | 35.42 | 13.56 | 71 | 16386 | 118267 | 90493723 |
| Bacterial test positive | 34.94 | 13.56 | 18 | 16439 | 5521 | 90606469 |
| Tetany | 34.02 | 13.56 | 14 | 16443 | 2570 | 90609420 |
| Palmar-plantar erythrodysaesthesia syndrome | 31.95 | 13.56 | 32 | 16425 | 27991 | 90583999 |
| Creatinine urine decreased | 31.71 | 13.56 | 8 | 16449 | 302 | 90611688 |
| Therapeutic product effect decreased | 31.69 | 13.56 | 6 | 16451 | 277565 | 90334425 |
| Platelet count decreased | 31.63 | 13.56 | 74 | 16383 | 136895 | 90475095 |
| Circulatory collapse | 31.31 | 13.56 | 30 | 16427 | 24874 | 90587116 |
| Herpes zoster | 31.01 | 13.56 | 59 | 16398 | 94585 | 90517405 |
| Product use issue | 30.34 | 13.56 | 11 | 16446 | 329908 | 90282082 |
| Peripheral swelling | 30.02 | 13.56 | 19 | 16438 | 413087 | 90198903 |
| Urine glucose/creatinine ratio increased | 29.80 | 13.56 | 7 | 16450 | 195 | 90611795 |
| Tri-iodothyronine free decreased | 29.63 | 13.56 | 8 | 16449 | 395 | 90611595 |
| Lower respiratory tract infection | 29.52 | 13.56 | 5 | 16452 | 250654 | 90361336 |
| Hepatic enzyme increased | 28.47 | 13.56 | 15 | 16442 | 360721 | 90251269 |
| Red cell distribution width increased | 28.45 | 13.56 | 21 | 16436 | 12186 | 90599804 |
| Maternal exposure during pregnancy | 28.38 | 13.56 | 15 | 16442 | 360048 | 90251942 |
| Death | 28.28 | 13.56 | 160 | 16297 | 456391 | 90155599 |
| Psoriatic arthropathy | 28.15 | 13.56 | 4 | 16453 | 228331 | 90383659 |
| Red blood cells urine positive | 27.89 | 13.56 | 13 | 16444 | 3212 | 90608778 |
| Red blood cell count decreased | 27.72 | 13.56 | 38 | 16419 | 46313 | 90565677 |
| Contraindicated product administered | 27.26 | 13.56 | 12 | 16445 | 320127 | 90291863 |
| Folliculitis | 26.60 | 13.56 | 3 | 16454 | 204350 | 90407640 |
| Neutrophil count decreased | 26.47 | 13.56 | 47 | 16410 | 71485 | 90540505 |
| Type 2 diabetes mellitus | 26.41 | 13.56 | 3 | 16454 | 203241 | 90408749 |
| Infusion site scar | 26.40 | 13.56 | 8 | 16449 | 598 | 90611392 |
| Flushing | 26.36 | 13.56 | 53 | 16404 | 88438 | 90523552 |
| Electrocardiogram T wave amplitude decreased | 24.91 | 13.56 | 7 | 16450 | 401 | 90611589 |
| White blood cells urine positive | 24.32 | 13.56 | 15 | 16442 | 6483 | 90605507 |
| Hypertension | 23.66 | 13.56 | 153 | 16304 | 457379 | 90154611 |
| Protein urine present | 23.33 | 13.56 | 15 | 16442 | 6969 | 90605021 |
| Musculoskeletal stiffness | 22.42 | 13.56 | 13 | 16444 | 296519 | 90315471 |
| Urobilinogen urine increased | 22.39 | 13.56 | 6 | 16451 | 288 | 90611702 |
| Renal cortical necrosis | 22.21 | 13.56 | 6 | 16451 | 297 | 90611693 |
| Insomnia | 22.05 | 13.56 | 119 | 16338 | 333355 | 90278635 |
| Blood thyroid stimulating hormone increased | 21.90 | 13.56 | 16 | 16441 | 9139 | 90602851 |
| Nitrite urine present | 21.87 | 13.56 | 8 | 16449 | 1071 | 90610919 |
| Visual acuity reduced | 21.81 | 13.56 | 24 | 16433 | 23386 | 90588604 |
| Thyroid cyst | 21.53 | 13.56 | 7 | 16450 | 659 | 90611331 |
| Basophil count increased | 21.37 | 13.56 | 8 | 16449 | 1143 | 90610847 |
| Gastrointestinal disorder | 21.26 | 13.56 | 10 | 16447 | 256677 | 90355313 |
| Infusion site discomfort | 21.09 | 13.56 | 9 | 16448 | 1807 | 90610183 |
| Monocyte count decreased | 21.04 | 13.56 | 10 | 16447 | 2581 | 90609409 |
| Aspartate aminotransferase increased | 20.96 | 13.56 | 53 | 16404 | 102884 | 90509106 |
| pH urine increased | 20.54 | 13.56 | 6 | 16451 | 395 | 90611595 |
| Chromaturia | 20.22 | 13.56 | 21 | 16436 | 19166 | 90592824 |
| Wheezing | 20.14 | 13.56 | 9 | 16448 | 238071 | 90373919 |
| Abdominal discomfort | 20.02 | 13.56 | 35 | 16422 | 477293 | 90134697 |
| Red cell distribution width decreased | 19.45 | 13.56 | 9 | 16448 | 2187 | 90609803 |
| Blood creatinine decreased | 19.35 | 13.56 | 13 | 16444 | 6502 | 90605488 |
| Asthma | 19.20 | 13.56 | 10 | 16447 | 242150 | 90369840 |
| Irritable bowel syndrome | 18.92 | 13.56 | 7 | 16450 | 207441 | 90404549 |
| Liver injury | 18.81 | 13.56 | 4 | 16453 | 170563 | 90441427 |
| Fibromyalgia | 18.74 | 13.56 | 7 | 16450 | 206262 | 90405728 |
| Pancreatitis acute | 18.71 | 13.56 | 26 | 16431 | 32089 | 90579901 |
| Lactic acidosis | 18.46 | 13.56 | 33 | 16424 | 50430 | 90561560 |
| Blister | 18.14 | 13.56 | 12 | 16445 | 254986 | 90357004 |
| Discomfort | 18.09 | 13.56 | 14 | 16443 | 274321 | 90337669 |
| Anaphylactic shock | 17.53 | 13.56 | 25 | 16432 | 31592 | 90580398 |
| Anxiety | 17.49 | 13.56 | 106 | 16351 | 309666 | 90302324 |
| Hypokalaemia | 17.49 | 13.56 | 58 | 16399 | 131058 | 90480932 |
| Ventricular tachycardia | 17.48 | 13.56 | 22 | 16435 | 24686 | 90587304 |
| Chest discomfort | 17.39 | 13.56 | 60 | 16397 | 138305 | 90473685 |
| White blood cell count increased | 17.37 | 13.56 | 38 | 16419 | 67203 | 90544787 |
| Swelling | 17.32 | 13.56 | 31 | 16426 | 419027 | 90192963 |
| QRS axis abnormal | 17.30 | 13.56 | 7 | 16450 | 1231 | 90610759 |
| Ill-defined disorder | 17.27 | 13.56 | 6 | 16451 | 184885 | 90427105 |
| Food interaction | 17.15 | 13.56 | 7 | 16450 | 1257 | 90610733 |
| Gait inability | 17.07 | 13.56 | 3 | 16454 | 146453 | 90465537 |
| Blood alkaline phosphatase increased | 17.03 | 13.56 | 31 | 16426 | 48048 | 90563942 |
| Hot flush | 16.97 | 13.56 | 35 | 16422 | 59453 | 90552537 |
| Eosinophil count increased | 16.90 | 13.56 | 16 | 16441 | 13065 | 90598925 |
| Drug ineffective | 16.72 | 13.56 | 166 | 16291 | 1384132 | 89227858 |
| Product dose omission issue | 16.69 | 13.56 | 17 | 16440 | 291670 | 90320320 |
| Immune thrombocytopenia | 16.65 | 13.56 | 16 | 16441 | 13310 | 90598680 |
| Product use in unapproved indication | 16.65 | 13.56 | 22 | 16435 | 336214 | 90275776 |
| Infection | 16.63 | 13.56 | 25 | 16432 | 362069 | 90249921 |
| Renal artery stenosis | 16.46 | 13.56 | 8 | 16449 | 2169 | 90609821 |
| Infusion site warmth | 16.45 | 13.56 | 8 | 16449 | 2170 | 90609820 |
| Acute kidney injury | 16.45 | 13.56 | 107 | 16350 | 320280 | 90291710 |
| Mobility decreased | 16.27 | 13.56 | 13 | 16444 | 250721 | 90361269 |
| Bone marrow infiltration | 16.17 | 13.56 | 6 | 16451 | 836 | 90611154 |
| Haematocrit decreased | 16.14 | 13.56 | 28 | 16429 | 41804 | 90570186 |
| Myelosuppression | 15.84 | 13.56 | 32 | 16425 | 53559 | 90558431 |
| Glucose urine present | 15.63 | 13.56 | 6 | 16451 | 918 | 90611072 |
| Infusion site rash | 15.46 | 13.56 | 8 | 16449 | 2475 | 90609515 |
| Impaired healing | 15.37 | 13.56 | 12 | 16445 | 234187 | 90377803 |
| Drug exposure before pregnancy | 15.37 | 13.56 | 6 | 16451 | 960 | 90611030 |
| Arthralgia | 15.37 | 13.56 | 81 | 16376 | 778441 | 89833549 |
| Tachycardia | 15.35 | 13.56 | 63 | 16394 | 157610 | 90454380 |
| Febrile neutropenia | 15.20 | 13.56 | 63 | 16394 | 158286 | 90453704 |
| Condition aggravated | 14.72 | 13.56 | 57 | 16400 | 595488 | 90016502 |
| Mean cell haemoglobin increased | 14.58 | 13.56 | 9 | 16448 | 3896 | 90608094 |
| Thyroid function test abnormal | 14.40 | 13.56 | 9 | 16448 | 3980 | 90608010 |
| Anion gap decreased | 14.26 | 13.56 | 5 | 16452 | 593 | 90611397 |
| Type I hypersensitivity | 14.07 | 13.56 | 9 | 16448 | 4146 | 90607844 |
| General physical health deterioration | 14.02 | 13.56 | 27 | 16430 | 355088 | 90256902 |
| Pollakiuria | 13.93 | 13.56 | 23 | 16434 | 32982 | 90579008 |
| Haematocrit increased | 13.85 | 13.56 | 8 | 16449 | 3070 | 90608920 |
| Ventricular arrhythmia | 13.74 | 13.56 | 9 | 16448 | 4312 | 90607678 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Chronic kidney disease | 34.90 | 15.99 | 39 | 6310 | 47202 | 42567784 |
| Lymphocyte count decreased | 20.60 | 15.99 | 23 | 6326 | 27786 | 42587200 |
| Palmar-plantar erythrodysaesthesia syndrome | 20.60 | 15.99 | 20 | 6329 | 20562 | 42594424 |
| Renal injury | 20.54 | 15.99 | 16 | 6333 | 12264 | 42602722 |
| Duodenal ulcer haemorrhage | 20.43 | 15.99 | 12 | 6337 | 5796 | 42609190 |
| Mucosal erosion | 20.07 | 15.99 | 7 | 6342 | 998 | 42613988 |
| Anaesthetic complication pulmonary | 18.94 | 15.99 | 4 | 6345 | 83 | 42614903 |
| Decreased appetite | 18.53 | 15.99 | 67 | 6282 | 193070 | 42421916 |
| Peptic ulcer | 17.38 | 15.99 | 9 | 6340 | 3403 | 42611583 |
| Hepatic function abnormal | 17.24 | 15.99 | 29 | 6320 | 51538 | 42563448 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Urine abnormality | 173.88 | 12.97 | 64 | 19360 | 9032 | 110560843 |
| Body tinea | 166.50 | 12.97 | 44 | 19380 | 2071 | 110567804 |
| Inhibitory drug interaction | 137.50 | 12.97 | 46 | 19378 | 4901 | 110564974 |
| Infection susceptibility increased | 134.68 | 12.97 | 44 | 19380 | 4354 | 110565521 |
| Lymphocyte count decreased | 133.12 | 12.97 | 97 | 19327 | 57146 | 110512729 |
| Urine leukocyte esterase positive | 128.69 | 12.97 | 41 | 19383 | 3745 | 110566130 |
| Poor quality sleep | 115.46 | 12.97 | 68 | 19356 | 28009 | 110541866 |
| Glucose tolerance impaired | 103.47 | 12.97 | 45 | 19379 | 9792 | 110560083 |
| Bone density decreased | 85.33 | 12.97 | 46 | 19378 | 15996 | 110553879 |
| Culture urine positive | 81.64 | 12.97 | 31 | 19393 | 4765 | 110565110 |
| Urine ketone body present | 80.72 | 12.97 | 29 | 19395 | 3817 | 110566058 |
| Purpura | 77.20 | 12.97 | 50 | 19374 | 24338 | 110545537 |
| Hyperlipidaemia | 74.94 | 12.97 | 57 | 19367 | 35791 | 110534084 |
| Impaired work ability | 68.84 | 12.97 | 48 | 19376 | 26371 | 110543504 |
| Impaired quality of life | 67.80 | 12.97 | 50 | 19374 | 29967 | 110539908 |
| Erythema | 61.63 | 12.97 | 149 | 19275 | 291298 | 110278577 |
| Torsade de pointes | 58.74 | 12.97 | 41 | 19383 | 22559 | 110547316 |
| Drug intolerance | 55.99 | 12.97 | 4 | 19420 | 406508 | 110163367 |
| Oral herpes | 55.57 | 12.97 | 48 | 19376 | 36032 | 110533843 |
| Blood urine present | 53.89 | 12.97 | 40 | 19384 | 24205 | 110545670 |
| White blood cell count decreased | 50.33 | 12.97 | 119 | 19305 | 229271 | 110340604 |
| Skin disorder | 48.44 | 12.97 | 48 | 19376 | 42865 | 110527010 |
| Alanine aminotransferase increased | 47.76 | 12.97 | 102 | 19322 | 183671 | 110386204 |
| Palmar-plantar erythrodysaesthesia syndrome | 44.67 | 12.97 | 45 | 19379 | 40980 | 110528895 |
| Joint swelling | 43.47 | 12.97 | 12 | 19412 | 442833 | 110127042 |
| Anaphylactoid reaction | 43.22 | 12.97 | 22 | 19402 | 6804 | 110563071 |
| Keratitis | 42.86 | 12.97 | 20 | 19404 | 5124 | 110564751 |
| Off label use | 39.32 | 12.97 | 134 | 19290 | 1500051 | 109069824 |
| Flushing | 38.06 | 12.97 | 67 | 19357 | 104669 | 110465206 |
| Treatment failure | 37.39 | 12.97 | 3 | 19421 | 277231 | 110292644 |
| Cataract | 37.20 | 12.97 | 57 | 19367 | 79428 | 110490447 |
| Drug interaction | 37.19 | 12.97 | 180 | 19244 | 500003 | 110069872 |
| Platelet count decreased | 36.64 | 12.97 | 106 | 19318 | 230337 | 110339538 |
| Specific gravity urine decreased | 36.00 | 12.97 | 11 | 19413 | 875 | 110569000 |
| Hypertension | 34.69 | 12.97 | 179 | 19245 | 509905 | 110059970 |
| Red cell distribution width increased | 34.62 | 12.97 | 27 | 19397 | 17575 | 110552300 |
| Band sensation | 33.88 | 12.97 | 11 | 19413 | 1067 | 110568808 |
| Red blood cell count decreased | 33.31 | 12.97 | 49 | 19375 | 65874 | 110504001 |
| Tetany | 33.12 | 12.97 | 15 | 19409 | 3589 | 110566286 |
| Neutrophil count decreased | 32.42 | 12.97 | 68 | 19356 | 120873 | 110449002 |
| Chronic kidney disease | 30.60 | 12.97 | 51 | 19373 | 76240 | 110493635 |
| Cellulitis | 30.51 | 12.97 | 68 | 19356 | 125948 | 110443927 |
| Wound | 30.36 | 12.97 | 3 | 19421 | 234434 | 110335441 |
| Aspartate aminotransferase increased | 29.81 | 12.97 | 78 | 19346 | 159858 | 110410017 |
| Therapeutic product effect decreased | 29.46 | 12.97 | 4 | 19420 | 244312 | 110325563 |
| Bacterial test positive | 29.36 | 12.97 | 18 | 19406 | 7959 | 110561916 |
| Infusion site scar | 29.27 | 12.97 | 8 | 19416 | 428 | 110569447 |
| Monocyte count decreased | 29.10 | 12.97 | 14 | 19410 | 3837 | 110566038 |
| Neutrophil count increased | 28.89 | 12.97 | 33 | 19391 | 34619 | 110535256 |
| Tri-iodothyronine free decreased | 28.86 | 12.97 | 8 | 19416 | 451 | 110569424 |
| Therapeutic product effect incomplete | 28.63 | 12.97 | 3 | 19421 | 223802 | 110346073 |
| Pericarditis | 27.86 | 12.97 | 3 | 19421 | 219111 | 110350764 |
| Arthropathy | 27.81 | 12.97 | 8 | 19416 | 287514 | 110282361 |
| Peripheral swelling | 27.00 | 12.97 | 19 | 19405 | 404015 | 110165860 |
| Rheumatoid arthritis | 26.07 | 12.97 | 10 | 19414 | 299603 | 110270272 |
| Creatinine urine decreased | 25.82 | 12.97 | 7 | 19417 | 363 | 110569512 |
| Haematocrit increased | 25.76 | 12.97 | 14 | 19410 | 4945 | 110564930 |
| Anaphylactic shock | 25.58 | 12.97 | 38 | 19386 | 51508 | 110518367 |
| White blood cells urine positive | 25.23 | 12.97 | 16 | 19408 | 7508 | 110562367 |
| Ventricular tachycardia | 25.01 | 12.97 | 37 | 19387 | 49972 | 110519903 |
| Basophil count increased | 24.81 | 12.97 | 10 | 19414 | 1800 | 110568075 |
| Gastrointestinal disorder | 24.79 | 12.97 | 6 | 19418 | 241946 | 110327929 |
| Infusion site discomfort | 24.66 | 12.97 | 10 | 19414 | 1827 | 110568048 |
| Herpes zoster | 24.59 | 12.97 | 57 | 19367 | 108322 | 110461553 |
| Insomnia | 24.11 | 12.97 | 126 | 19298 | 360464 | 110209411 |
| Hypokalaemia | 23.49 | 12.97 | 78 | 19346 | 182370 | 110387505 |
| Systemic lupus erythematosus | 22.95 | 12.97 | 8 | 19416 | 254330 | 110315545 |
| Product use in unapproved indication | 22.80 | 12.97 | 27 | 19397 | 447350 | 110122525 |
| Red cell distribution width decreased | 22.75 | 12.97 | 10 | 19414 | 2231 | 110567644 |
| Peptic ulcer | 22.59 | 12.97 | 15 | 19409 | 7604 | 110562271 |
| Gamma-glutamyltransferase increased | 21.98 | 12.97 | 39 | 19385 | 61270 | 110508605 |
| Psoriatic arthropathy | 21.96 | 12.97 | 4 | 19420 | 196757 | 110373118 |
| Mean cell haemoglobin increased | 21.51 | 12.97 | 13 | 19411 | 5604 | 110564271 |
| Urine glucose/creatinine ratio increased | 21.36 | 12.97 | 5 | 19419 | 142 | 110569733 |
| Lower respiratory tract infection | 21.33 | 12.97 | 8 | 19416 | 243098 | 110326777 |
| Protein urine present | 21.26 | 12.97 | 17 | 19407 | 11467 | 110558408 |
| Duodenal ulcer perforation | 21.21 | 12.97 | 3 | 19421 | 177697 | 110392178 |
| Nitrite urine present | 21.08 | 12.97 | 8 | 19416 | 1227 | 110568648 |
| Inappropriate schedule of product administration | 20.95 | 12.97 | 5 | 19419 | 203632 | 110366243 |
| Contraindicated product administered | 20.44 | 12.97 | 9 | 19415 | 248258 | 110321617 |
| Product use issue | 20.37 | 12.97 | 15 | 19409 | 311680 | 110258195 |
| Urticaria | 20.34 | 12.97 | 110 | 19314 | 318747 | 110251128 |
| Blood alkaline phosphatase increased | 20.32 | 12.97 | 41 | 19383 | 70894 | 110498981 |
| Contusion | 20.28 | 12.97 | 88 | 19336 | 233273 | 110336602 |
| Fibromyalgia | 20.13 | 12.97 | 3 | 19421 | 170906 | 110398969 |
| pH urine increased | 20.02 | 12.97 | 6 | 19418 | 447 | 110569428 |
| Red blood cells urine positive | 19.86 | 12.97 | 12 | 19412 | 5173 | 110564702 |
| Helicobacter infection | 19.65 | 12.97 | 4 | 19420 | 181873 | 110388002 |
| Thyroid cyst | 19.65 | 12.97 | 6 | 19418 | 476 | 110569399 |
| Visual acuity reduced | 19.35 | 12.97 | 26 | 19398 | 32147 | 110537728 |
| Hepatic function abnormal | 19.20 | 12.97 | 46 | 19378 | 89249 | 110480626 |
| Infusion site rash | 19.18 | 12.97 | 9 | 19415 | 2334 | 110567541 |
| Eosinophil count increased | 19.17 | 12.97 | 21 | 19403 | 21037 | 110548838 |
| Renal cortical necrosis | 19.16 | 12.97 | 6 | 19418 | 518 | 110569357 |
| Circulatory collapse | 18.95 | 12.97 | 30 | 19394 | 42963 | 110526912 |
| Type 2 diabetes mellitus | 18.94 | 12.97 | 4 | 19420 | 177228 | 110392647 |
| Secondary adrenocortical insufficiency | 18.91 | 12.97 | 11 | 19413 | 4423 | 110565452 |
| Musculoskeletal stiffness | 18.89 | 12.97 | 13 | 19411 | 279809 | 110290066 |
| Coronary artery disease | 18.85 | 12.97 | 40 | 19384 | 71650 | 110498225 |
| Haematocrit decreased | 18.68 | 12.97 | 38 | 19386 | 66079 | 110503796 |
| Mean cell haemoglobin concentration increased | 18.33 | 12.97 | 7 | 19417 | 1092 | 110568783 |
| Infusion site warmth | 18.28 | 12.97 | 8 | 19416 | 1765 | 110568110 |
| Blood lactate dehydrogenase increased | 18.26 | 12.97 | 30 | 19394 | 44304 | 110525571 |
| Blood thyroid stimulating hormone increased | 18.20 | 12.97 | 16 | 19408 | 12285 | 110557590 |
| Blood creatinine decreased | 17.93 | 12.97 | 14 | 19410 | 9123 | 110560752 |
| Urobilinogen urine increased | 17.88 | 12.97 | 6 | 19418 | 645 | 110569230 |
| Drug exposure before pregnancy | 17.54 | 12.97 | 6 | 19418 | 683 | 110569192 |
| Folliculitis | 17.48 | 12.97 | 4 | 19420 | 167649 | 110402226 |
| Chest discomfort | 17.02 | 12.97 | 68 | 19356 | 173780 | 110396095 |
| Electrocardiogram T wave amplitude decreased | 16.52 | 12.97 | 6 | 19418 | 815 | 110569060 |
| Asthma | 16.41 | 12.97 | 12 | 19412 | 250279 | 110319596 |
| Leukocyturia | 16.29 | 12.97 | 8 | 19416 | 2292 | 110567583 |
| Drug ineffective | 16.25 | 12.97 | 180 | 19244 | 1520360 | 109049515 |
| Bone marrow infiltration | 16.19 | 12.97 | 6 | 19418 | 862 | 110569013 |
| Product dose omission issue | 15.78 | 12.97 | 20 | 19404 | 321762 | 110248113 |
| Gastrooesophageal reflux disease | 15.73 | 12.97 | 68 | 19356 | 179908 | 110389967 |
| Maternal exposure during pregnancy | 15.72 | 12.97 | 13 | 19411 | 254870 | 110315005 |
| Rash maculo-papular | 15.71 | 12.97 | 38 | 19386 | 74184 | 110495691 |
| Blood cholinesterase decreased | 15.54 | 12.97 | 5 | 19419 | 471 | 110569404 |
| Anaesthetic complication pulmonary | 15.44 | 12.97 | 4 | 19420 | 174 | 110569701 |
| Muscle injury | 15.42 | 12.97 | 3 | 19421 | 140804 | 110429071 |
| Duodenal ulcer haemorrhage | 15.10 | 12.97 | 12 | 19412 | 8025 | 110561850 |
| Tachycardia | 14.99 | 12.97 | 79 | 19345 | 226566 | 110343309 |
| Loss of personal independence in daily activities | 14.82 | 12.97 | 4 | 19420 | 150016 | 110419859 |
| Mobility decreased | 14.78 | 12.97 | 12 | 19412 | 237410 | 110332465 |
| Mucosal erosion | 14.74 | 12.97 | 8 | 19416 | 2816 | 110567059 |
| Ill-defined disorder | 14.03 | 12.97 | 5 | 19419 | 156848 | 110413027 |
| General physical health deterioration | 13.98 | 12.97 | 34 | 19390 | 425261 | 110144614 |
| Pain in jaw | 13.97 | 12.97 | 29 | 19395 | 51148 | 110518727 |
| Food interaction | 13.81 | 12.97 | 7 | 19417 | 2145 | 110567730 |
| Blood urea increased | 13.68 | 12.97 | 30 | 19394 | 54927 | 110514948 |
| Chromaturia | 13.65 | 12.97 | 21 | 19403 | 29339 | 110540536 |
| Infusion site pain | 13.53 | 12.97 | 16 | 19408 | 17403 | 110552472 |
| Irritable bowel syndrome | 13.44 | 12.97 | 6 | 19418 | 164209 | 110405666 |
| Thyroid function test abnormal | 13.43 | 12.97 | 8 | 19416 | 3359 | 110566516 |
| Prostatitis | 13.15 | 12.97 | 9 | 19415 | 4792 | 110565083 |
| Blood bilirubin increased | 13.09 | 12.97 | 36 | 19388 | 75936 | 110493939 |
| Thyroid stimulating immunoglobulin | 13.07 | 12.97 | 3 | 19421 | 78 | 110569797 |
| Inflammation | 13.01 | 12.97 | 9 | 19415 | 193229 | 110376646 |
| Type I hypersensitivity | 12.99 | 12.97 | 10 | 19414 | 6383 | 110563492 |
| White blood cell count increased | 12.99 | 12.97 | 42 | 19382 | 96800 | 110473075 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | A02BA01 | ALIMENTARY TRACT AND METABOLISM DRUGS FOR ACID RELATED DISORDERS DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) H2-receptor antagonists |
| ATC | A02BA51 | ALIMENTARY TRACT AND METABOLISM DRUGS FOR ACID RELATED DISORDERS DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) H2-receptor antagonists |
| FDA MoA | N0000000151 | Histamine H2 Receptor Antagonists |
| CHEBI has role | CHEBI:35480 | analgesic |
| CHEBI has role | CHEBI:37961 | H<small><sub>2</sub></small>-receptor antagonist |
| CHEBI has role | CHEBI:49201 | anti-ulcer drug |
| CHEBI has role | CHEBI:50183 | P450 inhibitor |
| CHEBI has role | CHEBI:60809 | adjuvant |
| MeSH PA | D000897 | Anti-Ulcer Agents |
| MeSH PA | D004791 | Enzyme Inhibitors |
| MeSH PA | D005765 | Gastrointestinal Agents |
| MeSH PA | D006633 | Histamine Antagonists |
| MeSH PA | D006635 | Histamine H2 Antagonists |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D065607 | Cytochrome P-450 Enzyme Inhibitors |
| MeSH PA | D065609 | Cytochrome P-450 CYP1A2 Inhibitors |
| FDA EPC | N0000175784 | Histamine-2 Receptor Antagonist |
Related Drugs by ATC class:
A02BA H2-receptor antagonists 6 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Heartburn | indication | 16331000 | |
| Upper gastrointestinal hemorrhage | indication | 37372002 | |
| Duodenal ulcer disease | indication | 51868009 | DOID:1724 |
| Zollinger-Ellison syndrome | indication | 53132006 | DOID:0050782 |
| Multiple endocrine adenomas | indication | 60549007 | |
| Indigestion | indication | 162031009 | |
| Gastroesophageal reflux disease | indication | 235595009 | DOID:8534 |
| Systemic mast cell disease | indication | 397016004 | DOID:349 |
| Gastric ulcer | indication | 397825006 | DOID:10808 |
| Upper GI Bleed Prevention | indication | ||
| Maintenance of Healing Duodenal Ulcer | indication | ||
| Pancreatic insufficiency | off-label use | 37992001 | |
| Urticaria | off-label use | 126485001 | |
| Prevention of Stress Ulcer | off-label use | ||
| NSAID-Induced Gastric Ulcer | off-label use | ||
| Impaired renal function disorder | contraindication | 197663003 | |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Malignant tumor of stomach | contraindication | 363349007 | DOID:10534 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 13.83 | acidic |
| pKa2 | 6.71 | Basic |
| pKa3 | 0.0 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Histamine H2 receptor | GPCR | ANTAGONIST | Kd | 6.14 | WOMBAT-PK | CHEMBL | |||
| 5-hydroxytryptamine receptor 2A | GPCR | Ki | 5.16 | PDSP | |||||
| Multidrug and toxin extrusion protein 1 | Transporter | IC50 | 5.92 | CHEMBL | |||||
| Multidrug and toxin extrusion protein 2 | Transporter | INHIBITOR | Ki | 5.10 | IUPHAR | ||||
| Histamine H2 receptor | GPCR | Kd | 6.58 | CHEMBL | |||||
| Histamine H2 receptor | GPCR | ANTAGONIST | Ki | 5.90 | IUPHAR |
External reference:
| ID | Source |
|---|---|
| 4018845 | VUID |
| N0000147147 | NUI |
| D00295 | KEGG_DRUG |
| 70059-30-2 | SECONDARY_CAS_RN |
| 152402 | RXNORM |
| C0008783 | UMLSCUI |
| CHEBI:3699 | CHEBI |
| SD9 | PDB_CHEM_ID |
| CHEMBL30 | ChEMBL_ID |
| CHEMBL1201051 | ChEMBL_ID |
| DB00501 | DRUGBANK_ID |
| D002927 | MESH_DESCRIPTOR_UI |
| 2756 | PUBCHEM_CID |
| 1231 | IUPHAR_LIGAND_ID |
| 3765 | INN_ID |
| 80061L1WGD | UNII |
| 101 | MMSL |
| 2261 | MMSL |
| 4448 | MMSL |
| 4449 | MMSL |
| 6098 | MMSL |
| d00140 | MMSL |
| 003415 | NDDF |
| 004987 | NDDF |
| 373541007 | SNOMEDCT_US |
| 83051006 | SNOMEDCT_US |
| 83532008 | SNOMEDCT_US |
| 4018844 | VANDF |
| 4018845 | VANDF |
| 80061L1WGD | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Cimetidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-8192 | TABLET, FILM COATED | 300 mg | ORAL | ANDA | 20 sections |
| Cimetidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-8204 | TABLET, FILM COATED | 400 mg | ORAL | ANDA | 20 sections |
| Cimetidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-8305 | TABLET, FILM COATED | 800 mg | ORAL | ANDA | 20 sections |
| Cimetidine Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0121-1025 | SOLUTION | 300 mg | ORAL | ANDA | 18 sections |
| cimetidine 200acid reducer | HUMAN OTC DRUG LABEL | 1 | 0363-0022 | TABLET, FILM COATED | 200 mg | ORAL | ANDA | 15 sections |
| Cimetidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-0053 | TABLET, FILM COATED | 200 mg | ORAL | ANDA | 20 sections |
| Cimetidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-0317 | TABLET, FILM COATED | 300 mg | ORAL | ANDA | 20 sections |
| Cimetidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-0372 | TABLET, FILM COATED | 400 mg | ORAL | ANDA | 20 sections |
| Cimetidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-0541 | TABLET, FILM COATED | 800 mg | ORAL | ANDA | 20 sections |
| CIMETIDINE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0440-1282 | TABLET | 400 mg | ORAL | ANDA | 15 sections |
| Cimetidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-626 | TABLET, FILM COATED | 400 mg | ORAL | ANDA | 20 sections |
| Cimetidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10544-627 | TABLET, FILM COATED | 300 mg | ORAL | ANDA | 20 sections |
| CIMETIDINE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-048 | TABLET, FILM COATED | 300 mg | ORAL | ANDA | 17 sections |
| CIMETIDINE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-265 | TABLET, FILM COATED | 400 mg | ORAL | ANDA | 20 sections |
| CIMETIDINE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16590-372 | TABLET, FILM COATED | 800 mg | ORAL | ANDA | 20 sections |
| CIMETIDINE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-531 | TABLET | 300 mg | ORAL | ANDA | 14 sections |
| CIMETIDINE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 21695-532 | TABLET | 400 mg | ORAL | ANDA | 14 sections |
| Cimetidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 33261-024 | TABLET, FILM COATED | 400 mg | ORAL | ANDA | 20 sections |
| Equate Cimetidine | HUMAN OTC DRUG LABEL | 1 | 49035-820 | TABLET, FILM COATED | 200 mg | ORAL | ANDA | 15 sections |
| Cimetidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-0499 | TABLET, FILM COATED | 300 mg | ORAL | ANDA | 20 sections |
| Cimetidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-0500 | TABLET, FILM COATED | 400 mg | ORAL | ANDA | 20 sections |
| Cimetidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-3574 | TABLET, FILM COATED | 400 mg | ORAL | ANDA | 21 sections |
| Cimetidine Hydrochloride Oral Solution | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50383-050 | SOLUTION | 300 mg | ORAL | ANDA | 18 sections |
| CIMETIDINE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50383-966 | SOLUTION | 300 mg | ORAL | ANDA | 17 sections |
| ACID CONTROLLER | HUMAN OTC DRUG LABEL | 1 | 51316-739 | TABLET, FILM COATED | 200 mg | ORAL | ANDA | 15 sections |
| Cimetidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51655-697 | TABLET, FILM COATED | 400 mg | ORAL | ANDA | 20 sections |
| TAGAMET | HUMAN OTC DRUG LABEL | 1 | 52183-223 | TABLET | 200 mg | ORAL | NDA | 16 sections |
| Cimetidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 53002-3280 | TABLET, FILM COATED | 300 mg | ORAL | ANDA | 20 sections |
| Cimetidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-3314 | TABLET, FILM COATED | 300 mg | ORAL | ANDA | 20 sections |
| Cimetidine | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-3315 | TABLET, FILM COATED | 400 mg | ORAL | ANDA | 20 sections |